Endocrine Abstracts

Objective: Therapeutic glucocorticoids (GCs) are commonly used in the treatment of chronic inflammatory disease. Unfortunately, their long-term administration is associated with deleterious systemic side effects including muscle atrophy. 11 beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) activates glucocorticoids within muscle, is increased with inflammation, and has previously been shown to mediate GC induced muscle wasting. We examined the role of 11 beta-hydroxyster...

Objective: Therapeutic glucocorticoids (GCs) are used to treat chronic inflammatory disease, due to their anti-inflammatory effects. Despite their efficacy, chronic exposure to GCs elicits undesirable side effects, including muscle atrophy. 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1) activates GCs within muscle, is induced by inflammation, and has previously shown to drive GC-induced muscle wasting. We examined the role of 11β-HSD1 in mediating muscle wasting i...

Introduction: Muscle atrophy is a major clinical complication of acute exacerbations (AE) in chronic obstructive pulmonary disease (COPD). The enzyme 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1) activates glucocorticoids (GCs) within muscle, is induced by inflammation, and has been shown to contribute towards GC-induced muscle wasting. In this study, we examined the role of 11β-HSD1 in this context using a murine model of COPD-AE in animals with transgenic globa...